Hepatic failure due to nevirapine treatment for HIV infection;Leversvigt udløst af nevirapinholdig HIV-behandling

Ugeskrift for Laeger

Volumn 167, Issue 46, 2005, Pages 4359-

  Mens, Helene ^a   Katzenstein, Terese L ^a  

^a Rigshospitalet   (Denmark)

Author keywords

[No Author keywords available]

Indexed keywords

NEVIRAPINE;

ARTICLE; CLINICAL PRACTICE; CONSERVATIVE TREATMENT; DEATH; DRUG SAFETY; HIGHLY ACTIVE ANTIRETROVIRAL THERAPY; HOSPITAL ADMISSION; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; LABORATORY TEST; LIVER FAILURE; PATIENT MONITORING; TIME SERIES ANALYSIS;

ADULT; ANTI-HIV AGENTS; ANTIRETROVIRAL THERAPY, HIGHLY ACTIVE; FATAL OUTCOME; FEMALE; HIV SEROPOSITIVITY; HUMANS; LIVER FAILURE, ACUTE; MALE; MEDICATION ERRORS; MIDDLE AGED; NEVIRAPINE; PATIENT EDUCATION;

EID: 28244438428     PISSN: 00415782     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (5)

1. www.viramune.com /aug. 2004.
2. Dieterich DT, Robinson PA, Love J et al. Drug-induced liver injury associated with the use of nonnucleoside reverse-transcriptase inhibitors. Clin Inf Dis 2004;38 (suppl 2):S80-9.
3. Serious adverse events attributed to nevirapine regimens for postexposure prophylaxis after HIV exposures - Worldwide, 1997-2000. MMWR Weekly 2001;49:1153-6.
4. Patel SM, Johnson S, belknap SM et al. Serious adverse cutaneous and hepatic toxicities associated with nevirapine use by non-HIV-infected individuals. J Acquir Immune Defic Syndr 2004;35:120-5.
5. Van Leth F, Phanuphak P, Ruxrungtham K et al. Comparison of first-line antiretroviral therapy with regimens including nevirapine, efavirenz, or both drugs, plus stavudine and lamivudine: a randomised open-label trial, the 2NN study. Lancet 2004;363:1253-63.